Skip To Content

Through an integrated medical, pharmacy, claims and legal approach, we deliver insights to help navigate the ever‑changing Medicare Secondary Payer landscape.

Recent blog posts

October 28, 2020 · Optum Workers' Comp and Auto No-fault
The RED BOOK® September 2020 update indicated Major Pharmaceuticals recently discontinued their formulation of tizanidine 4 mg tablets. Read more...
October 20, 2020 · Optum Workers' Comp and Auto No-fault
The National Alliance of Medicare Set-Aside Professionals (NAMSAP), now known as the National Medicare Secondary Payer Network, continues to hit it out of the park at their annual conference. Read more...
October 14, 2020 · Clinical Team
The U.S. Food and Drug Administration (FDA) reported that the brand-name opioid analgesic, Duragesic (fentanyl transdermal system), manufactured by Janssen Pharmaceuticals, Inc., is being discontinued. According to the FDA’s website, Janssen made a business decision to permanently discontinue all Duragesic transdermal systems and indicated they should be maintained on formularies until the last produced batch expires on July 31, 2021 to maintain continuity of the reimbursement process. No additional information was provided on Janssen’s website related to its business decision. Read more...
October 09, 2020 · Optum Workers' Comp and Auto No-fault
The Centers for Medicare and Medicaid Services (CMS) released Version 3.2 of the Workers’ Compensation Medicare Set-Aside Arrangement (WCMSA) Reference Guide, which clears up how pricing is determined for services rendered at a major medical center. Read more...
September 29, 2020 · Clinical Team
The U.S. Food and Drug Administration (FDA) has issued a labeling change requiring the Boxed Warning and other precautions included in prescribing information to be updated for all benzodiazepines. Read more...
<< Previous      Next >>
Page 2 of 7

Subscribe today to receive our latest blogs, articles and more.

Subscribe now button
Clinical Connection
Policy Matters